Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease

Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson’s disease: a thorough QT/QTc study

(2014) Boaz Mendzelevski et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Pharmacological Treatment of Parkinson Disease

(2014) Barbara S. Connolly et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease

(2014) Robert A. Hauser et al.   MOVEMENT DISORDERS

Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease

(2013) F. Stocchi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease

(2013) Julián Solís-García del Pozo et al.   Expert Opinion On Drug Safety

Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms

(2013) Makoto Naoi et al.   Expert Review of Neurotherapeutics

Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial

(2013) Lina Zhang et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity

(2013) Jasmin Bartl et al.   JOURNAL OF NEURAL TRANSMISSION

Rapid onset of efficacy of rasagiline in early Parkinson’s disease

(2013) Sandro Zambito Marsala et al.   NEUROLOGICAL SCIENCES

Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson’s disease

(2012) François Viallet et al.   CURRENT MEDICAL RESEARCH AND OPINION

Rasagiline

(2012) Sheridan M. Hoy et al.   DRUGS

Indirect Comparisons of Adverse Events and Dropout Rates in Early Parkinson's Disease Trials of Pramipexole, Ropinirole, and Rasagiline

(2012) Francisco J. Zagmutt et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

‘‘70th Birthday Professor Riederer’’ Induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (−)deprenyl: a way to a disease-modifying therapy?

(2012) Wakako Maruyama et al.   JOURNAL OF NEURAL TRANSMISSION

Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease

(2011) F. Stocchi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Safety of rasagiline for the treatment of Parkinson's disease

(2011) Santiago Perez-Lloret et al.   Expert Opinion On Drug Safety

The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?

(2011) Jack J. Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Rasagiline

(2011) Ronald E. Wilson et al.   NEUROLOGIST

Efficacy and tolerability of rasagiline in daily clinical use - a post-marketing observational study in patients with Parkinson’s disease

(2010) H. Reichmann et al.   EUROPEAN JOURNAL OF NEUROLOGY

Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline

(2010) Tamar Goren et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinsonʼs Disease in the UK Setting

(2009) Alan Haycox et al.   DRUGS & AGING

The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline

(2009) Orit Bar-Am et al.   JOURNAL OF NEUROCHEMISTRY

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transtelephonic Home Blood Pressure to Assess the Monoamine Oxidase-B Inhibitor Rasagiline in Parkinson Disease

(2008) William B. White et al.   HYPERTENSION

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS